The investment-linked policy, compared

An investment-linked policy bundles two things that a property-literate reader is used to seeing kept apart: insurance, which is a cost, and a fund, which is an asset. You are not buying a container the way equity in a property is a container for a claim on rent and price. You are buying pre-packaging — the insurer does the fund selection, the underwriting, the administration and the paperwork in one product — and what you are selling, in MAS's own words, is the cost of finding out what that packaging actually costs you. That is not a knock on the product. It is the question this page answers before you sign anything.

If you hold one already, or an adviser has just shown you one, the honest first move is to separate the two halves in your head: the cover, and the fund. Everything below does that, in the order the rest of this site covers a property: mechanics, eligibility, citizenship, tax, borrowing, the point of sale, estate, the twelve questions, who is on the business side of the deal, and what the person selling it to you actually earns.

The mechanics: where your premium actually goes

MAS defines an ILP as a life insurance policy providing both protection and investment benefits: it pays out on death, total permanent disability or critical illness depending on the cover you bought, and it carries a surrender value based on the value of units held in the underlying sub-fund. Your premium buys units in one or more sub-funds; the insurer then sells some of those units each period to pay for the insurance cover and its own charges, and the rest stays invested.

MAS groups the charges into four layers, from its 2015 consultation on ILP disclosure: an entry or surrender charge at the product level, mainly distribution cost; insurance and administration fees at the product level; the sub-fund's own collective-investment-scheme fees; and the insurer's own extra management charge on top of the fund manager's. Every one of those layers sits between your premium and the units you actually end up holding.

• A worked example from MAS's own model Product Highlights Sheet, on a S$5,000 annual premium: Premium Allocation rate 20% in Year 1, 35% in Year 2, 55% in Year 3 — meaning only S$1,000 of Year 1's premium buys units before any sales charge.
• A 5% sales charge or bid-offer spread on top of that allocation.
• Fund manager's annual management charge 1.0%-1.5% of NAV, capped at 3%.
• The insurer's own additional annual management charge, 0.1%-0.5% of NAV on top of the fund manager's.
• Cost of insurance in Year 1, S$77 in the same model example, rising with age in later years.
• A policy fee of S$5 a month regardless of which sub-fund you hold.

How that Year 1 entry charge is quoted depends on which of two ways the insurer builds the policy. Front-end loading takes most of the early premiums for the insurer's distribution and administration cost, with the share that buys units rising gradually to 100%. Back-end loading buys 100% of units from day one and recovers the same cost later, through a surrender charge if you cash out within a set period. MAS's 2015 paper worked one entry-charge example at 81% of the Year 1 premium under the simplified single-charge method it was proposing at the time — a figure worth sitting with before you assume a 20% allocation rate is the whole story.

None of this is guaranteed to stay put, either. The insurer can vary its fees and charges over the life of the policy, though most contracts state the maximum it may charge, and the Policy Contract, Product Summary and Product Highlights Sheet are where that ceiling is written down — not in whatever an adviser tells you verbally.

Two independent illustrations land on the same order of magnitude for what all of this costs over time. The Kopi Notes' comparison case, a 35-year-old non-smoking male buying S$500,000 of 20-year term cover: about S$700-900 a year for the term policy alone, against a total ILP cost of roughly 2.5%-4.0% of fund value a year, with most regular-premium ILPs taking 10-15 years for the account value to exceed premiums paid and 3-7 years just to catch up to buying the same funds directly. And my own arithmetic on a round-number illustration: S$3,000 a year for 20 years is S$60,000 paid; a fund earning 5% a year before costs, with 3.0% a year of ongoing cost (net 2.0%), reaches about S$72,900 at year 20; the same fund at 0.3% a year of cost (net 4.7%) reaches about S$96,100 — a gap of roughly S$23,200 that has nothing to do with what the market did and everything to do with the four layers above.

Eligibility: who is allowed to sell you this, and how

Buying an ILP is not like buying a unit trust off a platform. By law you are meant to go through an advisory process: fact-find, analysis, a written Recommendation, implementation, then a periodic review, usually annual. At point of sale you should receive Your Guide to Life Insurance, a Product Summary, a Policy Illustration where relevant, and the Product Highlights Sheet specific to ILPs, and you sign a reference checklist at the end. The insurer must disclose every cost and charge, including any commission paid to the representative, inside the Policy Illustration.

Who is allowed to hand you those documents is itself restricted. A tied agent can only offer the products of the one insurer they represent — the Financial Advisers Act's one-principal rule means a representative acts for a single principal at a time, and that principal supervises them. A firm or representative may call itself 'independent' only if it takes no commission or benefit from a product provider that could bias the recommendation, and is free of any restriction on what it may recommend. You can check a firm on MAS's Financial Institutions Directory and an individual on the Financial Institution Representatives Register before you sign anything.

There is a fourth route that skips the adviser relationship entirely: Direct Purchase Insurance, a class of simple term and whole-life products bought straight from the insurer with no financial advice, no commission and a lower premium than a comparable advised product. It cannot be investment-linked — DPI is pure protection — but it is the cleanest available comparison for the insurance half of what an ILP sells you, at a price with the distribution cost stripped out.

You also get 14 days after receiving the policy document to change your mind under the free-look period, with premiums refunded less any medical expenses the insurer incurred assessing you — and, on an ILP specifically, less any change in the market value of the units you were allocated in the meantime. Miss that window and you are into whatever surrender-charge schedule the policy carries for the rest of its early years.

Funding it: cash, CPFIS, SRS — and what each route actually allows

Most ILPs are funded the plain way, from income, as a regular premium. Two other routes exist and each comes with its own eligibility test, which is where citizenship and residency status actually bite on this page — not through a stamp duty, because there isn't one, but through who is allowed into the scheme at all.

CPF Investment Scheme. CPFIS is open only to CPF members — in practice Singapore Citizens and Permanent Residents with CPF accounts, since work-pass holders generally do not accrue CPF as employees. Under CPFIS-OA and CPFIS-SA you can hold ILPs alongside unit trusts, annuities, endowments and government securities, but only Ordinary Account savings above S$20,000 and Special Account savings above S$40,000 may be invested; for members 55 and above the S$20,000 OA reserve still applies. CPF Board does not endorse any provider or product, and reminds members plainly that ILP policy and administrative fees make the CPFIS route cost more than buying the underlying fund directly.

Supplementary Retirement Scheme. SRS is open to Singapore Citizens, PRs and foreigners alike, which makes it the one funding route on this page where citizenship changes the number rather than the access: SRS tax relief is capped at S$15,300 a year for Citizens and PRs and S$35,700 for foreigners, for Year of Assessment 2026. Whether a specific insurer will let you fund an ILP with SRS money varies by product — one insurer's own page states its ILPs take cash only, not SRS funds, while other search results describe SRS funding single-premium insurance products generally. Ask the insurer directly for the specific policy; do not assume either answer.

Borrowed money is the route this page does not recommend, and it is covered under Borrowing below.

Citizenship status: what actually changes, and what does not

If you have read the property pages on this site, you will be used to a ladder: Singapore Citizen, Permanent Resident, foreigner, and the FTA nationals of the United States, Switzerland, Liechtenstein, Norway and Iceland, who are taxed as citizens for Additional Buyer's Stamp Duty. That ladder exists because buying residential property triggers a stamp duty keyed to your status. Buying an ILP triggers no stamp duty at all — it is a personal insurance and investment contract, not a conveyance — so the ABSD ladder simply has nothing to attach to here. Say that plainly rather than force-fitting it: the FTA-national equivalence that matters so much elsewhere on this site does not carry over to what you are buying today.

What citizenship actually changes for an ILP is which funding route you can use, covered above — CPFIS is CPF-members only, SRS is open to all three tiers at different relief caps — and, for US persons specifically, a tax and access problem that has nothing to do with Singapore's own citizenship categories at all.

A commercial guide to US tax exposure for Singapore-based Americans lists investment-linked policies explicitly as needing PFIC review, alongside CPFIS and SRS unit trusts, Ireland- or Luxembourg-domiciled UCITS ETFs, and S-REITs. Its own caveat is worth repeating: CPF or MAS approval of a product does not override the US PFIC test, and each sub-fund inside an ILP needs its own review before a US person relies on that classification for a filing.

Separately, secondary guides report Singapore banks and insurers taking an uneven line on onboarding US persons at all: private-banking arms are reported more willing, retail arms more restrictive, and the stated reason is the compliance burden FATCA places on a foreign financial institution servicing a US person, plus the fact that an institution not registered with the US SEC cannot lawfully offer certain investment products to one even once the account exists. If you are a US citizen or green-card holder shopping for an ILP in Singapore, expect that friction before you expect a quote.

Tax: what an ILP costs you, and what it does not

Start with what does not apply, because it is the largest part of the tax section on every other page on this site. There is no Buyer's Stamp Duty, no Additional Buyer's Stamp Duty, no Seller's Stamp Duty and no property tax on an investment-linked policy, because none of those are conveyancing or property-holding taxes and an ILP is neither. What is left is narrower and specific to the product.

Life Insurance Relief does not apply to an ILP where the investment component is a fundamental consideration of the policy — IRAS excludes it by name. If your CPF contributions already run S$5,000 or more in a year the relief is unavailable to you regardless; below that, CPF relief and life insurance relief together are capped at S$5,000, and an ILP is not the vehicle that gets you there.

On the investment side, Singapore has no capital gains tax, and gains from shares and financial instruments held as personal investments are generally not taxable unless the pattern of dealing amounts to trading — the same 'badges of trade' logic IRAS applies to a habitual property flipper. An ILP's own account-value growth is not separately taxed to you as income in the way a salary or rental receipt is.

If you fund the policy through SRS, the tax relief sits on the contribution, not the product — S$15,300 for Citizens and PRs, S$35,700 for foreigners, for Year of Assessment 2026 — and is identical whether the SRS money buys an ILP, a unit trust or a fixed deposit; the ILP itself earns you nothing extra on the tax side for being investment-linked.

For a US person, the account is not tax-transparent the way it might feel. A US citizen or green-card holder reports Singapore rental income and property gains on Form 1040 regardless of residence, and the same worldwide-income principle extends to an ILP once it is classified as a PFIC: mark-to-market or excess-distribution tax treatment and an annual Form 8621 filing, on top of whatever Singapore does with the policy. The Foreign Earned Income Exclusion does not help here either way — it exempts pay for personal services, not investment returns.

Borrowing: why this page does not have an LTV or a TDSR

Every property page on this site spends real space on Loan-to-Value, TDSR and MSR, because a property is usually bought partly with a bank's money against the asset itself. An ILP is not built to be bought that way, and nothing in MAS's ILP regime — Notice 307's mandatory disclosure, valuation and audit requirements — contemplates a lender taking security over your policy the way a bank takes a mortgage over a flat.

That does not mean leverage is absent from an ILP; it means it shows up in two narrower places, both worth naming plainly rather than leaving out because they do not fit the property template. First, some ILP sub-funds are themselves permitted to borrow or gear inside the fund, under MAS Notice 307's non-mandatory standards on investment guidelines and sub-fund borrowing limits — leverage you never personally arranged, sitting inside the wrapper you hold. Second, once a policy has built enough cash value, most insurers let you take a policy loan against the surrender value rather than surrendering the policy outright, at a rate the insurer sets; whatever you do not repay is deducted from the eventual claim or surrender payout. That is the closest thing an ILP has to a mortgage, and it is a loan against your own money, not against the market's.

What this page actively does not recommend is financing the premium itself — a personal loan, a line of credit, or an equity loan drawn against your flat, used to fund a single or regular ILP premium. The arithmetic works against you twice over: you are paying loan interest on top of a product that already carries 2.5%-4.0% a year of its own cost in the early years on independent estimates, and unlike a property, the ILP has no rental income to offset the financing cost with. If you are seriously considering this, read the equity-loan page on this site and the private-credit page before you read another word about ILPs.

Where reno, A&A and rebuild sit on this page: they don't — here CONTROL is the fund menu

On a property page, renovation, addition-and-alteration and rebuild are where CONTROL shows up: the owner can change the asset itself, within planning limits. There is no physical asset to renovate here, so that spoke does not transplant, and it would be dishonest to force it in. What plays the same role — your ability to change the outcome rather than just receive it — is fund switching and the small set of policy adjustments the contract allows, covered fully under C10 in the twelve questions below. Read that section as this page's version of the reno chapter.

The point of sale: the paperwork that binds you, in place of conveyancing

A property purchase has two clocks and a conveyancer standing between offer and completion. An ILP has no lawyer and no completion date, but it has an equivalent binding moment: the advisory process runs fact-find, analysis, a written Recommendation, implementation and an annual review, and you sign a reference checklist once the Product Summary, Policy Illustration and Product Highlights Sheet have been handed over. That checklist, not a conveyancing lawyer, is what confirms you received the documents that actually matter.

Two features of the paperwork are worth reading rather than skimming. The product-level Product Highlights Sheet is capped at four pages excluding appendices, in a minimum 10-point font, specifically so the fee structure cannot be buried in small print across twenty pages — read those four pages before the glossy brochure. And a partial surrender, later in the policy's life, is only permitted if the units you would keep are still worth at least S$1,000 in MAS's own model wording; below that threshold the insurer can simply refuse a partial cash-out and you are left choosing between staying in fully or surrendering fully.

If something goes wrong after the sale, the route is: raise it with the financial institution first, then the Financial Industry Disputes Resolution Centre within six months of the institution's final reply, then legal action as the last resort. FIDReC's mediation carries no claim limit; adjudication is capped at S$100,000 for claims filed before 1 July 2024 and S$150,000 from that date. MAS itself does not resolve commercial disputes or award compensation — it acts on misconduct such as fraud, misleading advice or misrepresentation.

Estate: the nomination gap that catches CPFIS and SRS holders

An ordinary ILP bought with cash offers two nomination routes, and they are meaningfully different. A trust nomination under section 49L of the Insurance Act is for the sole benefit of your spouse and children; you give up your own rights over the policy once it is made, and the proceeds generally sit outside your estate and are protected from your creditors if you are later made bankrupt. A revocable nomination under section 49M only directs where the death proceeds go — you keep full ownership and can revoke it any time without the nominee's consent, but it carries no creditor protection.

Neither route is available if you hold the ILP through CPFIS or SRS — the insurer's own nomination mechanism explicitly does not apply to those policies. Nor does an ordinary CPF nomination reach it: a CPF nomination covers your Ordinary, Special, MediSave and Retirement Account balances and CPF LIFE premiums, but by CPF Board's own listing it excludes property bought with CPF, Dependants' Protection Scheme payouts, and CPF Investment Scheme holdings — which is exactly where a CPFIS-held ILP lives. The practical result: an ILP bought through CPFIS or SRS can fall through both nomination systems at once and default into your general estate, distributed under your will or, if you have none, under intestacy — a genuinely easy gap to miss, because most people who nominate at all assume the CPF nomination they already made covers everything CPF-adjacent.

If estate planning is the reason you are looking at an ILP at all — using the death benefit to pass money outside probate — check which of the three routes, ordinary insurance nomination, CPF nomination, or plain will, actually reaches the specific policy you are buying, before you assume any one of them does. The wills and trusts pages on this site cover the general mechanics; this is the product-specific trap.

The voice: twelve questions, in plain words

Two questions sort a reader on the property pages of this site: are you borrowing to buy, and once you hold it, are you lending it out. Together they build a four-way grid — cash and own-use, cash and let-out, borrow and own-use, borrow and let-out — because a property can be financed with debt and can generate rental income, independently of each other. An ILP mostly cannot do either in the property sense: there is no rental market for a life policy, and, as covered under Borrowing, nothing in the regime is built for a lender to take security over one. So the same two questions still sort you, but onto a different, narrower grid.

Q1, are you borrowing to buy, becomes: are you funding premiums from cash flow (the default), from CPFIS or SRS (self-funding through a scheme with its own eligibility test, covered above), or with borrowed money (a personal loan or an equity loan against your home, which this page does not recommend, for the reasons under Borrowing). Q2, once you hold it are you lending it out, becomes: are you drawing on the cash value before maturity — through a partial surrender, subject to the S$1,000 minimum-remaining-unit rule, or a policy loan against the surrender value, which is in effect the insurer lending against your own asset. Hold both questions in mind through C0-C11 below; property's four boxes do not exist here, but the same instinct — know what you are funding this with, and know whether you are drawing on it early — still does the sorting.

C0. The play: balance sheet or cash flow?

Neither, cleanly — an ILP is a hybrid of a consumption item and an investment, bundled by design. The insurance half is a recurring cost, like any premium; the fund half behaves like a unit trust holding, minus the extra layers of charge described under Mechanics. The Kopi Notes' own conclusion, from its worked comparison, is blunt about which half usually wins for a given buyer: buy term and invest the rest outperforms an ILP for most 25-45 year olds with a 10-20 year horizon; an ILP only wins where you need both cover and investment in one product and genuinely cannot afford to buy them separately.

C1. Balance sheet: what you own and what you owe

What you own: units in one or more sub-funds, valued at their prevailing bid price, plus a death, TPD or critical-illness benefit that runs alongside the fund but is not the same asset as it. What you owe: nothing, by default — an ILP carries no acquisition debt the way a mortgaged property does. The one liability that can appear on your side of the ledger is a policy loan you have taken against the surrender value, which sits as a deduction against what you would otherwise be paid.

C2. Cash flow: what moves in and out, and when

Out: your premium, regular or single. In: nothing, in the ordinary case — there is no rent-equivalent income unless the specific product carries a cash-back or income rider, and most do not. Money only comes back to you on a partial surrender, a full surrender, maturity, or a claim. The funding gap to watch is the premium itself: if you stop paying past whatever grace period the contract allows, the insurer keeps selling units to cover the insurance and administration charges, and once the remaining units cannot cover those charges the policy lapses — a real cash-flow trap on a product often sold on the promise of flexibility.

C3. Profit and loss: which is not the same as cash

On a property, P&L differs from cash flow because loan principal is cash out but not an expense. On an ILP the same separation exists for a different reason: the Premium Allocation rate and entry charge mean a large share of your early cash outlay never buys a unit at all — it pays the insurer's distribution cost. In MAS's own model example, only S$1,000 of a S$5,000 Year 1 premium buys units before the sales charge even applies. Your cash flow says you paid S$5,000; your account's actual profit and loss, that year, reflects a small fraction of it working for you. Confusing the two is exactly the mistake the operator's frame exists to stop, on this page as much as on any property one.

C4. Carry: income minus financing cost

There is no financing cost in the property sense unless you have taken a policy loan or borrowed to fund the premium, so 'carry' here is better read as net cost of carry: the ongoing charge load — roughly 2.5%-4.0% of fund value a year in early years on independent estimates — set against whatever the sub-fund actually returns. My own illustration: a fund earning 5% a year before cost, with 3.0% a year of ongoing cost, nets 2.0% and reaches about S$72,900 after 20 years of S$3,000 premiums; the same fund at 0.3% a year of cost nets 4.7% and reaches about S$96,100. The gap, roughly S$23,200, is carry lost to structure, not to the market.

C5. Give and get: the trade in plain words

• You give: premiums, for as long as the policy runs; the liquidity of that money for the same period; and, in the early years, a large slice of each premium to distribution and entry charges before any of it becomes a unit.
• You get: insurance cover for the sum assured, for as long as premiums keep the policy in force; whatever units remain, net of every layer of charge, payable at maturity, surrender or claim; and, if you nominate correctly, a route for the death benefit to reach a named person outside the general estate.

C6. Exposed to: what can move against you

• Sub-fund market performance: MoneySense states plainly that returns are not guaranteed and you can potentially lose the entire value of your investment.
• The insurer's own right to revise fees and charges, up to whatever maximum the contract states.
• Rising cost of insurance as you age, which can eat further into the units backing your account value, especially once the policy is decades old.
• The premium-allocation schedule itself, if you are still in the early years when the allocation rate is lowest.

C7. For how long: the horizon you are committing to

Longer than the marketing conversation usually implies. Independent estimates put the break-even point, where the account value first exceeds total premiums paid, at 10-15 years for most regular-premium ILPs, and 3-7 years just to catch up to what you would have if you had bought the underlying fund directly and paid for term cover separately. Read the Policy Illustration for the specific product's own projection before assuming either figure applies to yours.

C8. Failure cascade: the order it goes wrong

The order is the point, on this page as much as on a leveraged property one, even though the mechanism differs. Weak sub-fund performance combined with rising insurance charges is this product's negative carry. That hits the units held inside the policy — its version of cash flow — reducing the account value, its version of P&L. Because there is no acquisition debt, there is no negative equity to speak of; instead, once the remaining units fall below what is needed to deduct the next charge, the insurer cannot collect it, and the policy lapses — a full write-off of both the cover and the invested value at once, which is this product's version of insolvency. Separately, cashing out early to avoid that outcome has its own cost: MAS's own standard risk wording states that early termination usually involves high costs and the surrender value may be less than total premiums paid.

C9. Liquidity: how fast it becomes money, and at what haircut

Slower and more expensive than most buyers expect going in. A partial surrender is available, but only if the units you keep afterward are still worth at least S$1,000 under MAS's model wording — fall below that and the insurer can decline it. A full surrender is always available, but a market guide's own figures describe surrender charges running as high as 100% of premiums paid in Year 1 on a typical ten-year declining schedule, easing only well into the policy's life. The 14-day free-look period is the one moment liquidity is close to free; after that, every early exit is priced.

C10. Control: the fund menu, not the building

This is where reno, A&A and rebuild live on a property page, and here it takes the shape of the policy's own adjustment features rather than anything physical. You can switch units between sub-funds, subject to a minimum switch amount — S$50 in MAS's model example — and a limited number of free switches before a charge applies. Some contracts allow adjusting the sum assured within limits, or a premium holiday if the contract and remaining units support it. What you cannot control is the sub-fund manager's own performance, the insurer's fee schedule within its stated ceiling, or the insurance-charge curve as you age — you are a price-taker on all three, choosing only your allocation across the menu the insurer built.

C11. The exit: how you get out, and what getting out costs

• Full surrender at any time, net of whatever the surrender-charge schedule costs you at that point in the policy's life.
• Partial surrender, if the units you would keep afterward clear the S$1,000 minimum.
• Maturity, or a claim on death, total permanent disability or critical illness, paying the sum assured and the account value according to the contract's terms.
• The 14-day free-look window right after purchase, the only exit priced at close to zero.

The business-to-business spoke: keyman insurance is where a company meets this product, and an ILP usually fails the test

A company does not buy an investment-linked policy on its own balance sheet the way it can own a condo or a fund stake — there is no corporate-ownership route into an ILP the way there is for property equity. The one place a business genuinely meets this product is keyman insurance: a policy a company takes out on a key employee, to fund the cost of replacing them or to protect against the loss of their contribution. IRAS's e-Tax Guide on keyman insurance premiums sets conditions for the premium to be tax-deductible, and two of them matter directly here: the policy must remain the property of the business with no assignment of benefits to the insured or their family, and — the one that rules out an ILP specifically — the policy must not provide for a cash surrender or investment value.

That second condition is a direct disqualifier. An investment-linked policy is, by definition, a policy with a surrender value based on the units it holds — the exact feature the keyman deduction rules exclude. A business buying keyman cover for the tax deduction should be buying pure term insurance, not an ILP, regardless of what an adviser pitches as 'insurance that also builds value'. The investment half of an ILP is precisely the half that breaks the deduction.

Beyond keyman cover, the regulatory line between an ILP's distribution and other investment products sold to businesses is worth naming: a restricted collective-investment scheme offered to accredited or institutional investors, or at S$200,000 or more per transaction, is exempt from MAS's scheme-authorisation and prospectus rules. Retail ILP distribution gets no such exemption — every retail ILP sale goes through the full fact-find, Product Summary, Policy Illustration and Product Highlights Sheet regime described under Eligibility above, whatever the size of the premium. A business large enough to be treated as an accredited investor does not get a shortcut on the ILP it buys for an individual employee; the exemption only reaches fund-style vehicles, not this product.

The realtor economics: what the person selling you this earns, and where the incentive points

The person on the other side of an ILP sale is not a CEA-registered property agent, and by law it cannot be one wearing both hats. MAS and CEA's joint reply, 16 December 2025, to a call for property agents to be regulated as financial advisers, states plainly that property agents are prohibited from acting as financial advisory representatives under the Financial Advisers Act — precisely so an agent cannot be incentivised to steer a client toward whichever product pays the agent more, property or financial. If your property agent is also pitching you an ILP, one of those two roles is not the one they are licensed for; check which.

What the actual representative earns sits inside the entry charge and Premium Allocation rate described under Mechanics — MAS calls this Layer 1 of the four-layer fee structure, and it is mainly distribution cost. The worked example is stark: a 20%/35%/55% allocation rate across Years 1-3 on a S$5,000 premium means the bulk of what you pay in the early years is funding something other than your own units, and MAS's 2015 paper separately worked an 81%-of-premium entry charge under the single-charge method it was then proposing. One unverified forum claim puts commission at around 50% of first-year premium on some products, sometimes 60% — I have not confirmed that figure against a primary source, and it conflicts with other guides' numbers, so treat it as a claim, not a fact, until MAS's own disclosed figures on a specific Policy Illustration say otherwise.

By law, the representative must disclose what they are paid for recommending, buying or selling the policy — MAS's Practice Note FAA PN-01 sets out when and how. That disclosure sits inside your own Policy Illustration. Ask for it, and read the number before you read the sales narrative around it.

Where the incentive points, including against the person writing this: a tied representative can only ever recommend their one insurer's shelf, so the range of 'right answers' is bounded before the conversation starts. An independent adviser is meant to be free of provider bias but is still, in almost every case, commission-paid rather than fee-based — paid more for recommending a product than for recommending none. The one route that pays the recommender nothing at all is Direct Purchase Insurance for the pure protection half, paired with buying the fund yourself for the investment half — which is also, on the independent illustrations above, usually the cheaper combination for a buyer with a 10-20 year horizon. Almost nobody is incentivised to walk you to that answer, because nobody earns a commission for it.

What this page does not know

• IRAS's own pages on Life Insurance Relief and on gains from sale of shares and financial instruments returned navigation only when fetched this run; the figures above rest on search-result excerpts of those pages, not a direct read of IRAS's own text.
• The LIA's ILP consumer guide and MAS's FAQ on accredited investors are both PDFs that did not render as readable text this run.
• What a specific insurer actually charges for a policy loan, in interest terms, is not on this page — it varies by insurer and is not something MAS standardises; ask for the specific rate before assuming one.
• Whether a given insurer will accept SRS funds for a specific ILP is unresolved in general and answered only product by product; ask before you assume either way.